Table 3.
Dose, diagnoses, time to progression and number of doses for patients with stable and progressive disease as best clinical response
| Response | Patient | Dose (mg/kg) | Diagnosis | TTP (weeks) | # of doses |
| SD | |||||
| 4001 | 0.05 | Uterine cancer | 20 | 21 | |
| 3004 | 0.1 | Melanoma | 19 | 16 | |
| 4004 | 0.1 | Melanoma | 15 | 16 | |
| 3005 | 0.2 | Mesothelioma | 18 | 16 | |
| 3009 | 0.2 | Mesothelioma | 17 | 15 | |
| 3006 | 0.25 | RCC | 18 | 13 | |
| 3008 | 0.25 | RCC | 16 | 13 | |
| Median | 18 | 16 | |||
| PD | |||||
| 3001 | 0.05 | Melanoma | 4 | ||
| 3002 | 0.05 | Melanoma | 7 | 8 | |
| 3003 | 0.05 | Breast cancer | 2 | 3 | |
| 4002 | 0.05 | HCC | 6 | 7 | |
| 4003 | 0.1 | Melanoma | 4 | 5 | |
| 3010 | 0.2 | Bladder cancer | 7 | 8 | |
| 3011 | 0.2 | Melanoma | 5 | 4 | |
| 3012 | 0.2 | Nasopharyngeal cancer | 4 | 5 | |
| 3013 | 0.2 | Breast cancer | 5 | ||
| 3015 | 0.2 | Neuroendocrine tumor | 7 | 8 | |
| 4005 | 0.2 | Melanoma | 2 | 3 | |
| 4006 | 0.2 | Breast cancer | 3 | 4 | |
| 4009 | 0.2 | Sarcoma | 3 | 4 | |
| 4010 | 0.2 | Melanoma | 7 | 6 | |
| 5001 | 0.2 | Ovarian cancer | 7 | 8 | |
| 5004 | 0.2 | Melanoma | 3 | 4 | |
| 3007 | 0.25 | Melanoma | 4 | 5 | |
| 4008 | 0.25 | Anal cancer | 7 | 8 | |
| 5002 | 0.25 | Colon cancer | 7 | 7 | |
| 5003 | 0.25 | Melanoma | 7 | 8 | |
| Median | 4.5 | 5 |
RCC, renal cell carcinoma; HCC, hepatocellular carcinoma.